Evan Rapoport
Evan Rapoport is co-principal of HedgeCo Networks, a hedge fund research and services firm. At HedgeCo, Mr. Rapoport oversees a hedge fund database of over 6,500 hedge funds, as well as a hedge fund user community of over 35,000 members. He has helped to create over two hundred hedge fund websites and has consulted on a substantial number of new hedge fund launches. Mr. Rapoport has been featured on CNBC and has appeared in various publications such as Newsweek Magazine, Forbes.com, Florida Trend and Registered Rep. Magazine.
Prior to helping found HedgeCo Networks, Mr. Rapoport was a Senior Vice President at Broadband Capital Management, a NASD member brokerage firm in New York City. At Broadband, Mr. Rapoport managed assets for institutions as well as high net worth clients and also participated in many private placements and PIPE transactions. Before Broadband, Mr. Rapoport was the youngest Senior Vice President in history at NYSE member Oscar Gruss' Private Client Group. He started his career in a Chairman's Council member's office at Paine Webber in NYC. Mr. Rapoport currently holds Series 7, 24, 63 and 55 securities licenses. He also holds a B.A. from the University of Florida.
Andrew Schneider is founder and co-principal of HedgeCo Networks, a hedge fund research and services firm. At HedgeCo, Mr. Schneider provides consulting services to both new and exsiting hedge funds. He also oversees a database of over 6,500 hedge funds, including a community of over 35,000 members. Mr. Schneider has been featured on CNBC, and in over two hundred other news publications.
He served in a number of high-profile Wall Street Firms such as Morgan Stanley and Prudential Securities. At Morgan Stanley, Mr. Schneider helped manage assets for institutions as well as high net worth clients while participating in many private placements, PIPE transactions and public offerings. He attended the State University of New York at Albany.
Mr. Schneider is also a member of the American Heart Association, and is extremely active in the research and development of alternative remedies to cardiac disorders.
